Randomized clinical trial on ivermectin versus thiabendazole for the treatment of strongyloidiasis.

ABSTRACT:

Background

Strongyloidiasis may cause a life-threatening disease in immunosuppressed patients. This can only be prevented by effective cure of chronic infections. Direct parasitologic exams are not sensitive enough to prove cure if negative. We used an indirect immune fluorescent antibody test (IFAT) along with direct methods for patient inclusion and efficacy assessment.

Methodology/principal findings

Prospective, randomized, open label, phase III trial conducted at the Centre for Tropical Diseases (Verona, Italy) to compare efficacy and safety of ivermectin (single dose, 200 µg/kg) and thiabendazole (two daily doses of 25 mg/Kg for two days) to cure strongyloidiasis. The first patient was recruited on 6(th) December, 2004. Follow-up visit of the last patient was on 11(th)

SUBMITTER: Bisoffi Z 

PROVIDER: S-EPMC3144183 | biostudies-literature | 2011 Jul

REPOSITORIES: biostudies-literature